Topic: Experimental Vaccines

4 chapters across the catalog

Vaccine Poverty
Episode 1365 56:02 - 1:00:05

1365: Vaccine Poverty

Scott Gottlieb and the Experimental Vaccine Gaffe

Former FDA Commissioner and current Pfizer board member Scott Gottlieb accidentally referred to the COVID-19 vaccine as "experimental" during a CNBC interview. He discussed the timeline for full FDA approval, suggesting it would provide employers with the impetus to mandate vaccinations. The hosts highlight the slip of the tongue as a rare admission of the vaccine's current status.

Attribution Science
Episode 1363 55:41 - 58:03

1363: Attribution Science

Nuremberg Code, Medical Ethics, Fact-Check Controversy

Fact-checkers have dismissed claims that the COVID-19 vaccine rollout violates the Nuremberg Code, arguing the code only applies to research trials and not general public health policy. Critics contend that because the vaccines are under Emergency Use Authorization, they remain technically experimental, making the code's protections against coerced medical participation relevant.

Obama's Pitch
Episode 114 46:48 - 51:46

114: Obama's Pitch

Novartis MF59 Adjuvant, FDA Approval and Liability Immunity

Pharmaceutical companies like Novartis are using experimental adjuvants such as MF59 in swine flu vaccines, despite a lack of long-term data on how they function. Health and Human Services Secretary Kathleen Sebelius signed a decree granting vaccine makers total immunity from liability for injuries caused by these shots. Critics argue the pandemic is being used as a loophole to conduct mass human testing of unapproved vaccine additives.

Forced Vaccinations
Episode 109 39:40 - 45:29

109: Forced Vaccinations

Barbara Loe Fisher, National Vaccine Information Center

Adam Curry plays a commentary from Barbara Loe Fisher of the National Vaccine Information Center regarding the H1N1 "novel" swine flu. Fisher warns that the CDC and FDA are using emergency powers granted after 9/11 to fast-track experimental vaccines without thorough testing. The segment highlights the $1 billion allocated to drug companies to produce vaccines that may contain genetically engineered viruses and reactive adjuvants.